Literature DB >> 12609838

Platelet factor 4 enhances generation of activated protein C in vitro and in vivo.

Arne Slungaard1, Jose A Fernandez, John H Griffin, Nigel S Key, Janel R Long, Donald J Piegors, Steven R Lentz.   

Abstract

Platelet factor 4 (PF4), an abundant platelet alpha-granule protein, accelerates in vitro generation of activated protein C (APC) by soluble thrombin/thrombomodulin (TM) complexes up to 25-fold. To test the hypothesis that PF4 similarly stimulates endothelium-associated TM, we assessed the influence of human PF4 on thrombin-dependent APC generation by cultured endothelial monolayers. APC generated in the presence of 1 to 100 microg PF4 was up to 5-fold higher than baseline for human umbilical vein endothelial cells, 10-fold higher for microvascular endothelial cells, and unaltered for blood outgrowth endothelial cells. In an in vivo model, cynomolgus monkeys (n = 6, each serving as its own control) were infused with either PF4 (7.5 mg/kg) or vehicle buffer, then with human thrombin (1.0 microg/kg/min) for 10 minutes. Circulating APC levels (baseline 3 ng/mL) peaked at 10 minutes, when PF4-treated and vehicle-treated animals had APC levels of 67 +/- 5 ng/mL and 39 +/- 2 ng/mL, respectively (P <.001). The activated partial thromboplastin time (APTT; baseline, 28 seconds) increased maximally by 27 +/- 6 seconds in PF4-treated animals and by 9 +/- 1 seconds in control animals at 30 minutes (P <.001). PF4-dependent increases in circulating APC and APTT persisted more than 2-fold greater than that of controls from 10 through 120 minutes (P < or =.04). All APTT prolongations were essentially reversed by monoclonal antibody C3, which blocks APC activity. Thus, physiologically relevant concentrations of PF4 stimulate thrombin-dependent APC generation both in vitro by cultured endothelial cells and in vivo in a primate thrombin infusion model. These findings suggest that PF4 may play a previously unsuspected physiologic role in enhancing APC generation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12609838     DOI: 10.1182/blood-2002-11-3529

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.

Authors:  Laurent O Mosnier
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

Review 2.  Regulation of long-term repopulating hematopoietic stem cells by EPCR/PAR1 signaling.

Authors:  Shiri Gur-Cohen; Orit Kollet; Claudine Graf; Charles T Esmon; Wolfram Ruf; Tsvee Lapidot
Journal:  Ann N Y Acad Sci       Date:  2016-03-01       Impact factor: 5.691

3.  Low levels of circulating platelet factor 4 (PF4, CXCL4) in subclinically hypothyroid autoimmune thyroiditis.

Authors:  S Görar; E Ademoğlu; A Çarlıoğlu; B Alioğlu; H Bekdemir; B Sağlam; Z Candan; R Üçler; C Culha; Y Aral
Journal:  J Endocrinol Invest       Date:  2015-07-05       Impact factor: 4.256

Review 4.  Thrombomodulin and its role in inflammation.

Authors:  Edward M Conway
Journal:  Semin Immunopathol       Date:  2011-07-31       Impact factor: 9.623

Review 5.  Utility of microfluidic devices to study the platelet-endothelium interface.

Authors:  Jevgenia Zilberman-Rudenko; Joanna L Sylman; Kathleen S Garland; Cristina Puy; Andrew D Wong; Peter C Searson; Owen J T McCarty
Journal:  Platelets       Date:  2017-03-30       Impact factor: 3.862

6.  Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT.

Authors:  M Anna Kowalska; Sriram Krishnaswamy; Lubica Rauova; Li Zhai; Vincent Hayes; Karine Amirikian; Jeffrey D Esko; Daniel W Bougie; Richard H Aster; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2011-07-19       Impact factor: 22.113

7.  Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications.

Authors:  Michele P Lambert; Lubica Rauova; Matthew Bailey; Martha C Sola-Visner; M Anna Kowalska; Mortimer Poncz
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

8.  Systemic blood coagulation activation in acute coronary syndromes.

Authors:  Anetta Undas; Konstanty Szułdrzyński; Kathleen E Brummel-Ziedins; Wiesława Tracz; Krzysztof Zmudka; Kenneth G Mann
Journal:  Blood       Date:  2008-10-17       Impact factor: 22.113

9.  PAR1 signaling regulates the retention and recruitment of EPCR-expressing bone marrow hematopoietic stem cells.

Authors:  Shiri Gur-Cohen; Tomer Itkin; Sagarika Chakrabarty; Claudine Graf; Orit Kollet; Aya Ludin; Karin Golan; Alexander Kalinkovich; Guy Ledergor; Eitan Wong; Elisabeth Niemeyer; Ziv Porat; Ayelet Erez; Irit Sagi; Charles T Esmon; Wolfram Ruf; Tsvee Lapidot
Journal:  Nat Med       Date:  2015-10-12       Impact factor: 53.440

Review 10.  Extravascular coagulation in hematopoietic stem and progenitor cell regulation.

Authors:  T Son Nguyen; Tsvee Lapidot; Wolfram Ruf
Journal:  Blood       Date:  2018-06-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.